Explore the role of #cvImaging in early stages of #HFpEF in this #JACCIMG state-of-the-art review: crucial for timely diagnosis and intervention. https://t.co/siTplc1n9h @JP_HFpEF

Raging against the Machine: The Human Side of the Story | NEJM AI

Patterns of Nonspecific Myocardial FDG Uptake in Patients Without Sarcoidosis With Normal CMR — Beware, not all FDG uptake on CardiacPET is cardiac sarcoidosis.

ODYSSEY-HCM: Mavacamten shows no significant improvement in outcomes for patients with symptomatic nonobstructive #cvHCM. Drs. Matt Martinez and Milind Desai explore the findings and discuss future treatment of HCM on this episode of 🎧 ACCEL Lite: https://t.co/L4hiTnmZuO

Hypertrophic cardiomyopathy: changing the paradigm of exercise prescription and competitive sport participation. Read this State-of-the-Art review just published in #EHJ @escardio @ESC_Journals #HCM https://t.co/aNNbpW1JPy

Discover the latest advancements in the field of #amyloidosis! 📚 From genomic screening to transthyretin amyloidosis and aortic stenosis, #JACCCardioOnc's Amyloidosis Hub covers it all. https://t.co/nOJSWzYd7Y #ACCMidEast #CardioOnc #ATTR #vhdAS @DrBonnieKy @ACCinTouch

Acoramidis 📉 cumulative CV outcomes in #ATTRCM vs placebo, w/ numerical differences by month 1 & 📈 through month 30 (53 events avoided/100 pts). Nearly 1/4 of events occurred in the first 6 months, underscoring the need for timely Tx https://t.co/MOo8sZYmtF #HFSA2025 #JACC

More incredible #CRISPR data with #Nexz published today in @NEJM -- this time 2 year data from the Phase 1 #ATTR polyneuropathy study. #TTR levels down 90% by day 28... and 92% at month 24! Improved neuropathy functionally and by #Nfl levels. Exciting prospects for #MAGNITUDE.

Building on the legacy of many, I'm incredibly excited that we have successfully translated our polygenic risk scores into a validated clinical assay @MassGenBrigham @broadinstitute, orderable by any clinician in the US today. 🧬To order: https://t.co/lmPHq57sKQ 🧬Announcement:

Presented at #ESCCongress: In patients with nonobstructive HCM, mavacamten did not significantly improve peak oxygen uptake or decrease symptoms as compared with placebo, and more patients had a reduction in LVEF with mavacamten. Full ODYSSEY-HCM phase 3 trial results:

🚨 AI won’t replace doctors… but it can prevent them from learning how to think. A critical article in @NEJM shows that if introduced too early in medical training, it weakens clinical reasoning. ✅ A good doctor will always need critical thinking. N Engl J Med 2025;393:786

🧲TTR amyloid cardiomyopathy: natural history & treatment response assessed by CV magnetic resonance @ESC_Journals #Cardiology #CardioEd #Whycmr #Amyloidosis #FOAMed

Primary LA cardiopathy was assoc w/ thrombotic events in transthyretin #amyloid #cardiomyopathy, independent of #AFib, CHA2DS2-VASc, & LA volume, unlike other phenotypes of LV hypertrophy. https://t.co/GFMIazOATV #echofirst #cvNuc #whyCMR #JACCIMG @leylaelifsade @benayozbay

High Sensitivity Troponin for Contemporary Risk Stratification in Wild-Type ATTR Amyloidosis @KMAlexanderMD #AHAJournals

📌 Conduction system pacing vs. biventricular pacing in patients undergoing atrioventricular node ablation 👉 https://t.co/E8eOGmugPO @EuropaceEiC @GiulioConte9 @Dominik_Linz @FraSantoroMD @AndyZhangMD @marcovitoloMD @DavideMei93 #Europace #arrhythmias #pacing

🚨New Publication Alert: Our Landmark Study Published in the European Heart Journal! We’re proud to share that our latest study demonstrates that EchoGo® Amyloidosis, Ultromics’ FDA-cleared AI tool, significantly improves the detection of cardiac amyloidosis using a single

#WhyCMR by LGE in sarcoidosis, new precision in prognosis? Large #UK cohort of biopsy-proven cardiac sarcoidosis finds that LGE extent was an independent predictor of VAs or device therapy. #JACCIMG offers a novel approach to arrhythmic risk stratification https://t.co/PDK5fsXjMt

Left ventricular myocardium-to-blood ratio >1.5 on 99mTc-HMDP SPECT/CT accurately detects ATTR-CM @helsinkiuni #cvnuc #amyloidosis. Editorial by @domcbenz @Unispital_USZ & @sarahcud @BrighamWomens Read now👉 https://t.co/eYFerR5cHM

PIEZO1 attenuates Marfan syndrome aneurysm development through TGF-β signaling pathway inhibition via TGFBR2 @ESC_Journals https://t.co/TO5MLDDBhM

https://t.co/kfwwQAkOsq